Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 11/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | TKT | P29401 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24962216 | 0.90 | TRPV4 (0.44) | TRPV4CNR2NR1H2NR1H3ALDH1A1 | |
| SCHEMBL23634137 | 0.87 | TRPV4 (0.42) | TRPV4ESR1ESR2PTGS2NR1H2 | |
| SCHEMBL22023804 | 0.84 | TRPV4 (0.40) | TRPV4CNR2CNR1ESR1ESR2 | |
| SCHEMBL22023779 | 0.84 | TRPV4 (0.40) | TRPV4ESR1ESR2PTGS2NR1H2 | |
| SCHEMBL19388193 | 0.83 | TRPV4 (0.47) | TRPV4NR1H2NR1H3ALDH1A1PKM | |
| SCHEMBL24876756 | 0.81 | TRPV4 (0.40) | TRPV4CNR2CNR1PTGS2NR1H2 | |
| SCHEMBL19388376 | 0.81 | TRPV4 (0.40) | TRPV4CNR2CNR1PTGS2NR1H2 | |
| SCHEMBL23007649 | 0.81 | TRPV4 (0.42) | TRPV4PTGS2ALDH1A1PKMTKT | |
| SCHEMBL21191574 | 0.80 | TRPV4 (0.39) | TRPV4CNR2CNR1ESR1ESR2 | |
| SCHEMBL22024373 | 0.80 | TRPV4 (0.39) | TRPV4CNR2CNR1PTGS2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | F2, C5, C9 | TRPV4 4694/4885CNR2 743/4885CNR1 606/4885 |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | TRPV4 4461/4885CNR2 2890/4885CNR1 2120/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | TRPV4 4461/4885CNR2 2890/4885CNR1 2120/4885 |
| US-10793504-B2 | Methods for cross coupling | F2, C5, C9 | TRPV4 4694/4885CNR2 743/4885CNR1 606/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TRPV4 4231/4885CNR2 2902/4885CNR1 2040/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TRPV4 4231/4885CNR2 2902/4885CNR1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.